Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)

Trial Profile

Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Nifurtimox (Primary) ; Benznidazole
  • Indications Chagas disease
  • Focus Therapeutic Use
  • Acronyms CHICAMOCHA-3; EQUITY
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2019.
    • 18 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2018.
    • 27 Nov 2015 According to ClinicalTrials.gov record, the treatment table has been amended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top